VentureBeat

Posts Tagged ‘healthcare-IT’

(UPDATED: Added screenshots and a link to video of the Myca patient-record interface.)

health-20-conference-logo.gifThe just-concluded Health 2.0 Conference in San Diego showcased some 30-odd startups and Web sites — with dozens more in the audience — all intent on using the Internet to improve patient care, streamline healthcare practices and bolster the ability of individuals to take charge of their own medical treatment. There’s lots more to say, and I hope to do so over the next few days.

For now, though, I want to highlight six startups with some big, and very different, ideas for reinventing the doctor-patient relationship — everything from making it deeper and more convenient to practically doing away with it altogether.

Visualize your medical records, keep your doctor on call

myca-logo-150px.gifIn their current form, even electronic medical records have a significant drawback: Most amount to little more than a digital representation of the paper forms that preceded them and consist largely of dense lines of biographical, family and medical information. (This is, of course, a fine place to start given that only 14 percent of all U.S. physicians use such systems in the first place, but it’s not exactly the end of the story.)

So in the same way that Web publications have adopted designs that exploit the advantages of the new medium (which also took time — even the pioneering online magazine Slate launched with a design that quaintly displayed page numbers just like a print publication), the folks at Myca have re-envisioned the display of medical records for the digital age. Unfortunately, the company doesn’t have any screen shots of its interface on its Web site, but their conference demo was quite striking. (You can see a brief 25-second example in this video produced for the conference; forward to 1:19 to see the Myca interface.)

Calling up a patient’s record displays her major health problem — asthma, say — surrounded by floating word tags for each of her other medical conditions, each sized larger or smaller depending on its severity. Clicking into any of these conditions zooms and centers it in the display, again surrounded by word tags for various important details, each of which can be expanded in place — for instance, visual displays of the patient’s recent medical appointments for the problem, or prescription drugs she’s taking, or X-rays and other medical images immediately available for viewing.

Here are two screenshots I just grabbed from the above-linked video (click for larger versions):

myca-interface-screenshot4.gifmyca-interface-screenshot3-255px.gif

“The whole point of the interface is to show you exactly what’s going on,” says Jay Parkinson, a young New York City doctor with a pioneering Internet-based practice who now serves as Myca’s chief medical officer. “It’s kind of the geek squad for medicine.” (For more about Parkinson, who grandly proclaims himself “the future” on his Web site, see this interview at the WSJ Health blog. Don’t miss the comments, where Parkinson squares off against critics of his approach.)

Read the rest of this entry »

TODAY’S HEADLINES:

txcell-logo-150px.gifFrance’s TxCell raises €11M for cell therapy – TxCell, a French cell-therapy biotech, raised €10.5 million ($16 million) in a second funding round. Investors included Auriga Partners, AXA Private Equity, Bioam Gestion, CDC Innovation and Seventure.

The biotech is developing a patient-specific cell therapy for the gastrointestinal autoimmune condition Crohn’s disease. Its technique involves isolating specific regulatory immune cells known as Tr1 cells, which help tamp down inflammation, from a patient’s blood. After selecting only Tr1 cells that respond to a particular biochemical stimulus (technically, a particular antigen) and reinfusing them into the patient, doctors would then activate the cells locally — here, presumably, in the gut — by administering the trigger antigen and thus “downregulating” the immune response that’s causing problems.

trihealix-logo-150px.gifHealthcare IT firm TriHealix takes in $7M – Norwalk, Conn.-based TriHealix, a healthcare IT provider focused on payment processing and consumer accounts, raised $7 million in a third funding round. Lemhi Ventures led the funding.

The TriHealix system integrates financial and medical information by tying together doctors and hospitals with insurers and patients. In theory, at least, the idea is to give patients a single card that handles both insurance and payments and may even provide a line of credit to handle deductibles and other out-of-pocket expenses. This approach is also supposed to free consumers from having to fill out reimbursement forms, as their medical information is forwarded directly to their insurer.

anodyne-health-logo-150px.gifHealthcare-software provider Anodyne Health acquires Piedmont Healthcare – Venture-backed Anodyne Health, an Alpharetta, Ga., developer of “revenue-cycle management” services for doctors and hospitals, agreed to acquire Charlotte, N.C.-based Piedmont Healthcare Management Group. The companies’ release is here.

The firms didn’t announce financial terms. Anodyne’s technology is designed to streamline the process of billing insurers and patients for medical services. Piedmont does much the same thing, only with a particular focus on emergency-room care. Anodyne is backed by Brook Venture Partners and Frontier Capital.

changehealthcare-new-logo-200px.gifFor empowered “medical consumers” to really transform the healthcare system, as Health 2.0 proponents would have, clear pricing and quality data for medical care is essential. Unfortunately, such information is currently in short supply.

The startup change:healthcare aims to fill that void with a revamped Web site, just launched this afternoon. And it’s a nifty idea, if unfortunately still flawed in execution. See our review at VentureBeat Life Sciences.

changehealthcare-new-logo.pngCan social networking help restrain, or even lower, healthcare costs? The Nashville, Tenn., startup change:healthcare is primed to find out.

Healthcare plans are inexorably forcing more cost-sharing on patients — a strategy some call YOYO, for “you’re on your own” — which means that the actual cost of medical care is looming larger for many Americans. Healthcare free-marketers think that’s a good thing, arguing that cost-consciousness will make people better medical consumers and cut down on the overuse of costly services. Their counterparts, meanwhile, worry that fewer people will be able to afford decent care and that individuals motivated to scrimp on medical care will tend to forego preventive check-ups that could catch serious conditions early, thus actually driving up costs over the long run.

Either way, we’re all likely to have to start paying more attention to what our medical care costs, not least because higher deductibles, coinsurance and co-payments are probably going to saddle us with a larger share of the bill. Yet medical pricing is murky to the point of almost complete opacity, since it’s difficult and at times almost impossible to find out what doctors or hospitals actually charge for an appointment or a procedure. Even then, costs can vary widely depending on how old a patient is, where she lives, whether she’s insured or not, and even what hospital or pharmacy she happens to step into.

It’s this informational void that change:healthcare hopes to address with a freshly revamped site that’s just gone live. The new service wraps together the startup’s previous two Health 2.0 services –MedBillManager, a subscription service for helping people manage complex medical bills, and FindYourDoc.com, a physician directory that change:healthcare took down several months back in anticipation of the redesign — and bolsters its social-network aspects, particularly the ability of users to share medical-cost information and rate their doctors or hospitals. The ultimate idea is to build up a database — one supplemented by data from employer healthcare billings, Medicare and other sources — that can help anyone shop around for high quality but inexpensive medical care.

We’ve covered change:healthcare in the past — see here and here, for instance — but I held off reviewing its offerings in light of the pending redesign. That was probably just as well, since FindYourDoc in particular had a slapdash feel to it, thanks to some odd display quirks and some gaps in hospital data that probably weren’t the site’s fault (it relied heavily on Medicare data at the time) but which were disconcerting nonetheless.

More after the jump:
Read the rest of this entry »

careseek-logo.gifThe Health 2.0 movement, as I’ve noted before, makes some big claims about the Internet’s power to transform the relationships between patients and doctors, hospitals, insurers and each other. Some of that is undoubtedly true, and there’s a fascinating amount of innovation going on in this area– helped along by a recent torrent of venture capital.

There’s a downside to the movement, though, and that’s a bizarre oversupply of sites that are all doing slight variations on the same thing. Were you able to pick a Health 2.0 site at random, chances are good you’d hit one of dozens of online physican directories, health-specific search sites or health “portals” with some sort of attached social community. (Or even a site doing some combination of these, such as the health-search-and-community site iMedix, which we reviewed here.)

Probably nowhere is the glut so severe as among sites that aim to help patients find — and sometimes compare — doctors. Consider, for instance, the case of CareSeek, a Solvang, Calif., startup that last year launched a doctor-rating service called, reasonably enough, NursesRateDoctors.com. The idea was straightforward: Let nurses, who are in an unmatched position to observe doctors and their treatment of patients, could dish anonymously about physicians worth seeing — and those to avoid.

But lots of other entrepreneurs had similar ideas for doctor directories and rating services. “When we started, our competitive analysis showed there were maybe six sites doing this,” says CareSeek founder Gale Wilson-Steele. “We recently counted 31. The doctor review and rating space is very big and very noisy. But it creates a problem — no one is going to go to all these sites and rate the same doctor 31 times.”

CareSeek sought its advantage by appealing specifically to nurses, who frequently chafe at the perceived lower status of their profession relative to doctors. The company built its own director of doctors (for some of the general difficulties that presents, see my dCard post) and then went all-out to attract the attention of nurses. “We did everything,” Wilson-Steele says. The company ran banner ads, attended trade shows and handed out gift certificates and chocolate bars bearing the message, “Help raise the bar in healthcare” and the site’s address. CareSeek even set up a laptop in a medical-uniform shop and offered a discount to nurses who agreed to rate a doctor on the spot. (More recently, it also established a partnership with an online nurses-uniform site.)

The idea is a variation on the old strategy of specializing in order to stand up to larger competitors (which in this case includes WebMD, RevolutionHealth, and — soon enough — Google Health). “We just have this specialized information,” Wilson-Steele says. “At some level, hundreds of patient reviews aren’t better than two or three good ones.”

More after the jump:

Read the rest of this entry »

(UPDATED: See below.)

google-health-logo-250px.gifWell, the WSJ says so in this somewhat breathless report that states Google will announce its long-awaited personal health-record service today.

My first thought was that the announcement was timed to get Google on the record in advance of the Health2.0 “Spring Fling” conference in San Diego next week, which will feature lots of talk about the role of the Internet in improving healthcare. Another possibility is that Google is pulling a bait-and-switch similar to that of Navigenics, which last November “announced” its personal-genomics service but held off launching it until — well, until not yet.

Yet a third possibility — and the most likely one to me — is that, as this CNET article states, Google CEO will merely “preview” Google Health at the annual meeting of the Healthcare Information and Management Systems Society, supposedly the largest healthcare IT meeting in the world. Whatever it is, don’t hold your breath; the WSJ itself states that “[i]t wasn’t clear when the Google service for creating personal health records will begin to be available for consumers to access.”

In fact, the WSJ article doesn’t actually describe Google Health in any sort of detail, and instead is largely devoted to pointing out the major challenges facing personal health records, many of which will sound familiar to regular readers here. These include:

  • Limited adoption of electronic medical-record systems. Only 14 percent of U.S. medical practices even use digital records, which will complicate the process of moving medical information to the Google system.
  • Incompatible electronic medical-record systems at hospitals and doctors’ offices. Because existing digital-record systems use different data formats, systems like Google’s will have to be able to import most, if not all, of them, pushing up complexity and cost.
  • Privacy. Third-party systems such as Google’s aren’t regulated by federal medical-privacy laws, giving providers plenty of freedom to, for instance, sell ads tailored to your medical profile. (Google told the WSJ that “trust between Google and our users is one of the absolute cornerstones of our business.”)

Unmentioned by the WSJ is another nagging question, which is the extent to which patients can “customize” their medical profile — which, when it comes down to it, means the ability to selectively share, edit or even delete information. As I’ve noted before, such customization could undermine the usefulness of health records to doctors, while limiting peoples’ freedom to edit them makes them a whole lot less “personal.”

To be sure, a preview by Schmidt is better than what we’ve seen so far — mostly screenshots of what appear to be leaked early prototypes of the Google Health site, plus a vague announcement of a Google Health pilot project in Cleveland. In fact, the CNET piece mentioned above actually delivers some of the goods, offering a brief description (but no screenshots) of the preview.

Among the intriguing new details: The service will allow customers to “customize” their health records, although CNET doesn’t say by how much; will be integrated with Google’s maps and email applications to allow people to more easily search for doctors and save their contact information; and will allow third-party widgets that work within the platform, such as one that might alert patients through Google’s calendar when it’s time for them to take medication.

It’s tempting to conclude that this steady drip-drip-drip of information is part of a master PR plan for generating maximum enthusiasm for the Google Health service. (If so, it’s working brilliantly.) As for the launch itself, I suspect we won’t be able to miss it when it actually happens. Accept no substitutes.

UPDATE: Google Health chief Marissa Mayer makes the official announcement in this blog post. The bottom line: A launch of Google Health is likely “in coming months,” but not now. There are some nifty screenshots, though — one of which we’ve basically seen before — but I’ve reproduced them both below for reference. (Click either for larger versions.)

google-health-official-screenshot-main-580px.gif

google-health-official-screenshot-profile-580px.gif

TODAY’S HEADLINES:

Microsoft launches $3M fund to support online health-improvement tools – Software giant Microsoft, hoping to make a splash at the annual meeting of the Healthcare Information and Management Systems Society in Orlando — don’t laugh; HIMSS is apparently the largest healthcare IT meeting in the world — announced a new $3 million fund intended to stimulate the development of online tools that “improve health.” In typical Redmond fashion, the fund will be known as the “Microsoft HealthVault Be Well Fund,” which is the sort of name only a committee could love.

Microsoft is soliciting grant applications in six areas ranging from primary and “secondary” prevention (essentially, the monitoring of vital signs such as blood pressure for hypertension or blood sugar for diabetes) to women’s and community health. The fund will make grants of up to $500,000, with selections made by “healthcare industry leaders” — read, representatives of Microsoft partners — chosen by the Microsoft Health Solutions Group.

Of course, funded applications must make use of Microsoft’s HealthVault platform, which we’ve written about here and here as a decidedly mixed bag of technologies and Web applications. Three million bucks sounds like a pretty trivial amount to spend to in an attempt to jump-start HealthVault, but I guess Microsoft has to start somewhere.

clarus-ventures-150px.gifClarus Ventures raises $660M life-science fund – Clarus Ventures, a Cambridge, Mass., VC firm, closed a second life-science fund of $660 million. The fund will aim to make investments of $20 million to $60 million in biotechnology, medical devices and specialty pharmaceuticals.

Clarus raised its first $500 million fund in Dec. 2006. That fund has made significant investments in a variety of life-science companies including Globus Medical (our coverage), Pelikan Technologies (our coverage) and Taligen Therapeutics (our coverage).

iverson-genetics-logo-150px.gifIverson Genetics raises $1.1M for blood-clotting tests, seeks $9.3M more – Iverson Genetic Diagnostics, a Seattle maker of molecular diagnostics, raised $1.1 million in a first funding round and hopes to close a $9.3 million second round within a few weeks, VentureWire reports. Individuals provided the first round of cash, and Iverson is courting a “strategic investor” — that is, a corporate or laboratory partner of some kind — for the second.

Iverson recently won FDA approval for a genetic test designed to predict patient response to warfarin, a commonly used generic blood thinner intended to prevent dangerous blood clots. Last August, the FDA required the drug’s manufacturers to note that certain genetic factors can help establish proper dosing of warfarin, which can cause internal bleeding at high doses. (See our coverage here.) Although two million people in the U.S. take warfarin every year, adoption of the genetic tests has been slow. Iverson is one of at least three companies now offering those tests, which Iverson plans to roll out first in the Seattle area.

TODAY’S HEADLINES:

progen-logo-150px.gifCellGate acquired by Australian cancer biotech ProGen for $2.5M –CellGate, a Redwood City, Calif., biotech working on new cancer drugs, sold itself to ProGen, an Australian biotech also focused on cancer, for the equivalent of about $2.5 million. The release is here. Needless to say, this represents a fire sale for a biotech that seems to have run out of time.

CellGate was pursuing drugs that aimed to shut down the growth of cancer cells either by inhibiting polyamine or by “turning down” the activity of cancer-related genes. ProGen will conduct an 18-month assessment of CellGate’s first drug candidate, a polyamine inhibitor that had already completed an early stage, phase I clinical trial, before deciding upon a mid-stage, phase II program. ProGen will also evaluate a stable of CellGate’s preclinical drug candidates.

ProGen will issue shares worth $1.5 million for CellGate’s assets, and will assume net liabilities of roughly another $1 million. The sale represents a significant loss for CellGate’s investors, including Healthcare ventures and New Enterprise Associates, who as recently as 2002 put $10 million into the company in a fourth funding round. I haven’t been able to piece together how much CellGate raised over its lifetime, although it’s certainly considerably more than that $10 million.

traversa-logo-150px.jpgTraversa raises $2M for RNAi-delivery technologies – Traversa Therapeutics, a La Jolla, Calif., biotech working on ways to deliver RNA-based drugs to their cellular targets, raised $2 million in a first financing round. Investors included San Diego Tech Coast Angels, Mesa Verde Venture Partners and Morningside Group.

Traversa’s work is intimately involved with RNA interference, a newly discovered technique for “silencing” disease-related genes using short strands of RNA that trigger a natural cellular mechanism for shutting down genes. Getting those short RNA molecules into cells in the first place, however, isn’t particularly easy.

Traversa claims to have solved that problem, although it doesn’t appear to be saying how. The company will license its RNA-delivery approach to drug companies, and also offers it for use as a drug-screening technology.

remitdata-logo-150px.gifRemitDATA, Web-based healthcare-service co., takes in $5M – Memphis, Tenn.-based RemitDATA, a provider of Web-based healthcare-data services, raised $5 million in a new funding round.Noro-Moseley Partners and SSM Partners provided the funding.

RemitDATA offers Web-based tools for individual physician practices designed to help them track insurance and Medicare reimbursements and scan paper records into digital form. The company also makes a sales-management tool for the homecare industry.

promedior-logo-150px.gifPromedior pulls down another $5.5M for fibrotic disease – Promedior, a Malvern, Pa., biotech focused on fibrotic disease, raised an additional $5.5 million as an extension to its first funding round. Polaris Venture Partners, Morgenthaler Ventures, HealthCare Ventures and Easton Capital participated in the financing.

Fibrotic disease is a general name for conditions that entail repeated bouts of inflammation followed by scarring that, over time, can lead to organ failure. Examples include heart failure, cirrhosis and kidney failure. Promedior aims to develop drugs that can slow or reverse the scarring process, and intends to begin clinical trials of its first drug candidate this year. The company previously raised $7 million in its first funding round.

Acrongenomics takes 11 percent stake in Molecular Vision – Acrongenomics, a Swiss company that acquires and develops life-sciences technology, took a 10.5 percent stake in Molecular Vision, a developer of credit-card sized diagnostic devices. Acrongenomics had previously announced its intent to acquire Molecular Vision, so presumably this is the first step in that plan. The release is here.

Hepatitis drug-developer Biolex withdraws IPO – Biolex Therapeutics, a Pittsboro, N.C., biotech developing ways to manufacture protein drugs in an aquatic-plant system, withdrew its planned $70 million IPO. We previously covered Biolex and its IPO dreams here.

NovaMin raises $2.5M for dental-care products – NovaMin, an Alachua, Fla., company working on tooth-remineralization products, raised $2.5 million in a third round of funding and expects another $2.5 million, VentureWire reports. Intersouth Partners provided the financing.

Cardious aims at $1.5M for heart-valve repair – Cardious, a Northfield, Minn., medical-device company working on a heart-valve bypass device, is raising $1.5 million in a first funding round, VentureWire reports. The company aims to raise the funds from angel investors. Cardious is developing an aortic-valve replacement that can be put in place on a beating heart, rerouting blood flow around the damaged valve.

(UPDATED: IAC put out a release this morning — see below.)

healthcentralcom-logo.gifThe HealthCentral Network, an Arlington, Va., collection of health-information sites, raised roughly $50 million, paidContent reports. Investors included some big names, include Barry Diller’s online media and commerce conglomerate IAC, Sequoia Capital, Carlyle Group and Polaris Venture Partners.

HealthCentral runs about 30 health-related Web sites, ranging from general-info offerings like HealthCentral.com to disease-specific sites such as OurAlzheimers.com and MultipleSclerosisCentral.com. (The company also owns the DrKoop.com name, although that site is no longer affiliated with the former Surgeon General.) The sites are all essentially clones of one another in style and appearance, and generally offer a grab-bag of general or disease-specific information and some seemingly sparsely attended forums.

HealthCentral doesn’t seem to produce much of its own content, either; it lists five different sources, including Harvard Health Publications, HealthDay, and Thomson, at the bottom of its sites. In other words, it’s difficult to see exactly what makes the business worth the sums investors are pouring into it, as you can easily find much the same stuff on a half-dozen other sites.

In short, the whole HealthCentral Network looks a lot like a crass money-grab — a minimal deployment of resources designed to catch, if not retain, the maximum number of eyeballs. Which means that this latest investment is simply the latest in a flood of hot money that’s been pouring into health and so-called Health 2.0 sites over the past year or so, a trend that’s looking more and more like an unsustainable bubble with every transaction.

We’ve covered several related launches such as Microsoft’s HealthVault, Kosmix RightHealth, HealthCare.com, Healthline, and a roundup of other startups here. Valleywag has more on HealthCentral in particular.

UPDATE: IAC issued a release on its investment this morning, which doesn’t move the ball forward in any meaningful way. But at least the deal is confirmed.

TODAY’S HEADLINES:

cogenesys-logo.jpgTeva acquires protein-therapeutic maker CoGenesys for $400M — CoGenesys, a Rockville, Md., protein-drug biotech spun out of Human Genome Sciences in 2006, has been acquired by Israel’s Teva Pharmaceutical Industries for $400 million in cash. The companies’ joint release is here.

CoGenesys, like its former parent HGS, is focused on the development of protein and peptide drugs for a variety of conditions. The company’s two lead drug candidates aim to treat neutropenia, a depletion of white blood cells that puts people at risk of serious infection, and heart failure.

Teva said the acquisition advances its recently revised strategic goal of pursuing biotech drugs (”biopharmaceuticals”) and generic biologics (”biogenerics”). It’s not entirely clear whether Teva is interested in pursuing CoGenesys’ actual drug pipeline or simply putting its manufacturing technology to use in Teva’s existing international biogenerics business. No biogenerics have been approved for use in the U.S.

viewray-logo-150px.gifViewRay takes in $25M for MRI radiation-therapy guidance — Gainesville, Fla.-based ViewRay, a developer of MRI-based cancer-radiation systems, raised $25 million in a second funding round. Investors included OrbiMed Advisors, Fidelity Biosciences, Aisling Capital and Kearny Venture Partners.

ViewRay claims its system will be the first to offer real-time “volumetric” imaging of tumors concurrent with radiation treatment, which ostensibly allows radiation oncologists to compensate for organ movement. The funding will go for additional staff and the manufacture and validation of advanced prototypes of the system. Our previous coverage of the company is here.

novamed-logo150px.jpgNovaMed, Chinese clinical-research outfit, receives $14M — NovaMed, a Chinese startup that performs outsourced commercial and clinical-trial management for Chinese and international drug companies, raised $13.8 million in a second funding round. Investors included Fidelity Asia Ventures, its US affiliate, Fidelity Biosciences, and Atlas Venture.

Founded in 2005 by a former AstraZeneca executive and a Chinese Internet entrepreneur, NovaMed essentially acts as a middleman for companies with drugs they’d like to sell or test in China. Depending on the client, NovaMed says it will do everything from running clinical trials and shepherding drugs through the Chinese regulatory process to manufacturing, distributing and selling pharmaceuticals.

The company had previously raised roughly $6 million. NovaMed said it will use the new funding to expand its operations and also to in-license new drugs for deveopment or sale in China.

Lumidigm takes in $7M for optical-fingerprint ID systems — Lumidigm, an Albuquerque, N.M., developer of multispectral fingerprint scanners, raised $7 million in a third funding round, VentureWire reports, citing a regulatory filing. Investors included Epic Ventures led the round, joined by new investor Sun Mountain Capital and existing investors Fort Washington Capital Partners, Motorola Ventures, Draper Fisher Jurvetson New England and Intel Capital. Lumidigm’s technology aims to read fingerprint information both from the skin surface and from subsurface layers to improve accuracy and foil attempts to spoof the technology.

Medical-software co. Compressus aims to close $14M round — Compressus, a Washington, D.C., software maker whose products link hospitals and doctors to government agencies for public-health monitoring and emergency response, is looking for an additional $1.3 million to close out a $14.3 million third funding round, VentureWire reports. The company, which was founded by three lobbyists, has so far raised more than $27 million from angel investors.

Channel Medical Partners aims for $150M med-tech fund — Channel Medical Partners, a Skokie, Ill., VC firm focused on medical-device investments, aims to raise a $150 million second fund, VentureWire reports. The new fund would be more than triple the size of its $40 million initial fund, raised in 2001. Channel aims to fund 12 to 15 startups with the new cash, and will concentrate on device firms, although it is open to investing in diagnostics, drug delivery and “specialty supply” companies as well.

(UPDATED: See below.)

imedix-logo.jpgFor all the fuss over “Health 2.0″ companies that hope to revolutionize the U.S. medical system by tapping the bottom-up information-sharing capabilities of the Web, the unfortunate fact is that many of them are busily piling into business areas that are already seriously overcrowded. Worse, many seem to have no business model at all. iMedix, a new site hoping to draw users into a community where they can share information about their medical conditions, illustrates both of these tendencies.

For starters, iMedix aims to stake out a position in both health-related search and patient-community building, neither of which is exactly a new idea. The Health 2.0 Wiki lists 11 different healthcare-community sites — a conservative count, as there are several others, including iMedix, it hasn’t yet rated — at least seven of which do much the same thing iMedix intends to do. These range from broad patient communities like DailyStrength and Inspire to communities focused on diseases such as diabetes and psychological disorders.

Online health search sites are even more common, running the gamut from Google’s health directory and Microsoft’s HealthVault to portal sites like WebMD and Healthline to human-organized sites such as Organized Wisdom.

The upshot of all this is that anyone hoping to make a splash in these areas had better have built one hell of a better mousetrap — which, of course, is exactly what iMedix claims to have done. Essentially, the site aims to put users in immediate touch with others who share similar medical or health interests, allowing them to chat in real time or send personal messages back and forth. It then aims to tap this community to improve its parallel health-info search service, inviting users to rate the sites returned by each search with a thumbs-up or a thumbs-down.

imedix-screenshot-2.gifAll of which is fine in broad outline — it’s the execution that leaves something to be desired. The iMedix opening screen is a fairly bare-bones affair (click on the image at left for a larger screenshot), offering a search bar and a list of “getting started” community options for finding your iMedix “friends,” seeing who’s online, and checking messages. It’s certainly a different approach from the crowd-the-page-until-it-groans tack that some online-health sites take, but information-packed it’s not.

imedix-screenshot-people.gifThe meat of the site lies in its online community, which users are encouraged to join by creating a profile, choosing an avatar and inputting their medical interests and any other personal information they care to share. A “People” page shows an array of other users and their profiles, each of which gives you the opportunity to initiate conversations and trade information. The effect, though, is a bit unsettling — it’s like looking at a wall of mugshots, all representing individuals pleading with you to chat with them or send them messages.

Of course, the moment you sign up, you’re up on the wall as well, unless you explicitly choose to change your setting to “offline” or “invisible.” The exposure can be immediate — within minutes of establishing my profile, I’d already received a message from a self-described Israeli biotechnology student who wanted to tell me all about a new “business initiative” that sounded suspiciously like a weight-loss scheme. Unlike other community sites, there are no online forums or any other way to take in or share info with others in a group — here, it’s all one-on-one. Whether this sort of thing works for others is a matter of individual preference, but it’s a little creepy for my taste.

iMedix is also fairly insistent about getting you to input as much personal information as possible. A progress bar at the top of the screen measures the “completeness” of your profile, and the site frequently asks if you’d like to add more information to your profile — for instance, after completing a search on some topic. Of course, this is all pseudonymous, but I can’t help wondering whehter people are really going to want to let their personal health interests, coupled with their age and location, hang out for everyone to see.

imedix-screenshot-search-fabry.gifThe site’s search function (see screenshot at left) has a few interesting gimmicks, most notably an autocomplete function that’s surprisingly good at filling out complex medical terms. The quality of search results, at least on rarer conditions, however, leaves something to be desired. I looked up Fabry disease, a rare congenital disorder, and the first entry returned was this almost information-free page. Google, by contrast, popped up a helpful resource page on the condition from the National Institutes of Health. The search function doesn’t seem to cope particularly well with symptoms, either — a search for “stabbing chest pain” returned a pair of forum posts from other sites instead of anything helpful. Supposedly user input will help hone the search results, but there’s little evidence so far that it’s had much effect.

Which is, perhaps, a little unfair of me, since iMedix only officially launched on Dec. 10. It’s entirely possible that the community features will prove wildly popular and the search results will skyrocket in quality. We’ll have to see, but so far, the hype over the site — such as its nomination for a “best new startup” award in the Crunchies — seems premature. Among other things, I found it odd that despite having what iMedix co-founder Iri Amirav told me were “thousands of users,” the site never displayed more than a dozen as being online at any given time.

Actually, the more I think about it, the stranger this site seems. In effect, iMedix users have only two sources of information — the intermittently useful search function and individual conversations with other users. Now, some of these people may be great resources — I didn’t have the time to chat with them to find out. The effect, though, is to give the site a conspicuously information-deprived feel. Some of this may simply reflect the fact that iMedix was founded by two Internet entrepreneurs with no medical or healthcare background at all. The company does claim to have an advisory board consisting of “strategic investors, successful internet entrepreneurs, information retrieval specialists, artificial intelligence professors and medical experts,” but it’s not exactly encouraging to see the medical experts listed last there.

The other mystery about iMedix is exactly how it plans to make money. Amirav says the site is exploring options for advertising — it already runs a few inconspicuous Google Adsense ads — but to call his plan “vague” would be an insult to vague plans. (It amounts to something like: Online health is a big business that’s growing quickly, so we’ll build out the site and advertisers will flock to us.) Of course, advertisers might be interested in aggregated data from iMedix users, but Amirav was adamant that the site will never share any user information with anyone, and implied that would include anonymized, aggregated data. That’s certainly a plus from the user perspective, assuming iMedix actually holds the line there, but it’s not at all clear how you sell advertising against an undefined, monolithic community.

All that said, iMedix is still very much in flux, and will undoubtedly continue to grow and change in response to feedback as long as its funding holds out. It’s certainly different, although whether that’s a good or bad thing remains to be seen.

UPDATE: So iMedix won a Crunchie for “best new startup.” I’m still not a fan, at least in its current incarnation.

TODAY’S HEADLINES:

transenterix-logo.gifTransEnterix gets $21M for minimally invasive GI surgery — TransEnterix (no Web site), a Research Triangle Park, N.C., device maker developing tools for “natural orifice” gastrointestinal surgery, raised $21 million in a first funding round. Investors included SV Life Sciences, Parish Capital Advisers and Synergy Life Science Partners.

According to the Web site for Synecor, a North Carolina incubator that founded TransEnterix, the company is at work on tools and devices for minimally invasive “trans-oral” surgery using an endoscope passed through the mouth and down the esophagus. This procedure is designed to enable surgeries through the stomach wall and other unspecified “natural entry points,” potentially in a way that could supplant minimally invasive laparoscopic procedures that require entry through the abdominal wall. Patients would be consciously sedated during the procedure.

The funding will allow TransEnterix to “deliver” its first-generation tools, presumably for use in clinical trials, and to fund development of next-generation devices.

bioheart-logo-150px.gifStem-cell developer Bioheart’s IPO postponed — Bioheart, a Sunrise, Fla., developer of a stem-cell-based heart therapy, has postponed its troubled IPO. Although the company doesn’t seem to have officially yanked it yet, odds are now good that it will.

Bioheart’s woes started last October, when it abruptly slashed its offering price and fired its underwriters. The company’s IPO has lingered on life support ever since. We gave readers some good reasons to be skeptical about Bioheart — which, notably, is backed by former football great Dan Marino, among others — as long ago as last July.

advancedmd-logo-150px.gifMedical-practice software provider AdvancedMD acquired by Francisco Partners — AdvancedMD, a Salt Lake City provider of Web-based medical-practice management software — now there’s a mouthful — announced that it was acquired by the private-equity firm Francisco Partners. Financial terms weren’t disclosed.

AdvancedMD, founded in 1999, sells a series of Web-based products designed to handle administration, billing and electronic medical records for physicians. The company had previously raised venture funding from Dominion Ventures, Windward Ventures and Hunter Capital. Francisco has already named a new CEO, and said that it intends to “leverage” the company’s success with “additional resources” to accelerate its growth.

peptimmune-logo-150px.jpgPeptimmune draws $8.2M for MS drug trials — Cambridge, Mass.-based Peptimmune, a biotech at work on drugs for autoimmune and metabolic conditions, raised $8.2 million in the first stage of its fourth funding round. The company anticipates closing a second tranche in the second quarter. Investors included New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Investors and Silicon Valley Bank Capital.

Peptimmune is focused on using protein fragments known as peptides to disrupt or otherwise modulate immune-system reactions associated with disease. Its lead candidate, PI-2301, is a “random sequence” peptide similar in certain respects to the approved drug Copaxone, which Peptimmune is currently testing against multiple sclerosis in early-stage human tests.

alimera-logo.gifAlimera Sciences aims for autumn IPO to fund diabetic eye-disease drug — Alimera Sciences, an Alpharetta, Ga., biotech focused on eye disease, is contemplating an IPO this fall, VentureWire reports (subscription required). The funds will ideally support the launch of the company’s first innovative product, a treatment for a blinding complication of diabetes known as diabetic macular edema.

Alimera, which started life as a specialty pharma that resold over-the-counter eye products, began development of its current candidate, Medidur, in 2005. The treatment, co-developed with the nanotech company pSvidia, is a tiny structure designed to be injected into the back of the eye, where it steadily emits a corticosteroid called fluocinolone acetonide. The idea is to provide the smallest possible quantity of the steroid directly to the back of the eye, where a fluid buildup in the retina steadily obscures vision. Many ophthalmologists currently treat the condition with steroid injections, although no drugs are approved for the disease.

Medidur is currently in late-stage, phase III human tests. Alimera expects data from that trial in late 2009 and could file for approval in 2010.

TODAY’S HEADLINES:

Autonomic Technologies raises $3M for neurostimulators — Menlo Park, Calif.-based Autonomic Technologies (no Web site), a medical device company developing some sort of neurostimulator, has raised $3 million of an intended $5 million first round of funding, PE Hub reports, citing a regulatory filing. Kleiner Perkins Caufield & Byers provided the cash, while the Cleveland Clinic is also listed as a shareholder.

The company appears to be pretty well stealthed, as so far I haven’t managed to turn up any telltale traces outside of this single report. Among other things, the Kleiner site, unsurprisingly, doesn’t even list Autonomic in its portfolio. One potential clue lies in the company’s name, as the phrase “autonomic technology” generally refers to software or a network that manages and corrects itself (IBM has been a big proponent of the idea, although it’s hard to tell from here if it’s classic IT hype or something real). So presumably the startup is pursuing neurostimulation that engages a “self-healing” response of some sort in the brain or central nervous system.

If anyone knows anything about what Autonomic is up to, feel free to give us a shout in comments or by email.

amplimed-logo.jpgCancer-drug developer AmpliMed draws $5M — Amplimed, a Tuscon, Ariz., biotech focused on cancer drugs, has raised $5 million of a planned $22 million third funding round, PE Hub reports, citing a regulatory filing. Investors included BioMed Venture Partners, Biotech Insight Ventures, Solstice Capital and Valley Ventures.

AmpliMed is working on a new type of chemotherapy drug — technically, a cytotoxic chemotherapy that targets all rapidly dividing cells in the body — that it claims may be substantially less toxic that most such drugs. The company’s lead candidate, which it calls Amplimexon, inhibits a compound called glutathione that appears to protect cancer cells from damage by “free oxygen” radicals, or single-atom oxygen ions that typically wreak havoc within cells. AmpliMed suggests that non-cancerous cells that also divide rapidly, such as those lining the gut, appear to weather the suppression of glutathione more hardily than tumor cells, which theoretically should accumulate loads of oxygen radicals and then self-destruct.

Amplimexon is currently in mid-stage human tests against pancreatic and skin cancer. The company also has two other cancer compounds in earlier stages of development.

canopy-financial-logo-150px.jpgCanopy Financial raises $15M for outsourced healthcare management — Canopy Financial, a San Francisco developer of healthcare information systems, raised $15 million in a first funding round. Granite Global Ventures provided the funding.

Canopy sells systems for managing “consumer-oriented” health plans such as health savings accounts or flexible spending accounts. These are plans that purport to reduce healthcare costs by making individuals “responsible” for their medical spending, in effect by requiring them to pay for doctor and hospital visits out of a pre-established and often tax-exempt account to which employers may or may not contribute.

Clinical diagnostics maker Laboratory Partners pulls in $16M — Palo Alto, Calif.-based Laboratory Partners (no Web site), a provider of diagnostic tests to hospitals and other healthcare providers, raised $16 million in a fourth funding round, VentureWire reports (subscription required). The company said the funding will allow it to pursue acquisitions in the field.

Investors in the round included Primus Capital Funds (which put up $10 million), Oxford Bioscience Partners, Chrysalis Ventures and Fort Washington Capital Partners Group. Lab Partners has previously raised $26 million in venture funding, VentureWire reports.

syndevrx-logo-150px.gifSynDevRx targets $11M for cancer drugs — SynDevRx, a Cambridge, Mass.-based biotech developing new cancer drugs, is looking to raise $11 million in a first funding round, VentureWire reports. The company is pursuing an anti-angiogenic compound — that is, a drug candidate intended to block the growth of new blood vessels in tumors — originally developed in the lab of Children’s Hospital researcher Judah Folkman.

SynDevRx, founded in 2007, says this family of comp